Q3 2017 13F Holders as of 9/30/2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
236M
-
Number of holders
-
115
-
Total 13F shares, excl. options
-
29.9M
-
Shares change
-
+2.89M
-
Total reported value, excl. options
-
$588M
-
Value change
-
+$66.4M
-
Put/Call ratio
-
0.05
-
Number of buys
-
77
-
Number of sells
-
-37
-
Price
-
$19.67
Significant Holders of Akebia Therapeutics, Inc. - Common Stock (AKBA) as of Q3 2017
142 filings reported holding AKBA - Akebia Therapeutics, Inc. - Common Stock as of Q3 2017.
Akebia Therapeutics, Inc. - Common Stock (AKBA) has 115 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 29.9M shares
of 236M outstanding shares and own 12.66% of the company stock.
Largest 10 shareholders include BlackRock Inc. (3.75M shares), EAGLE ASSET MANAGEMENT INC (3.04M shares), Novo Holdings A/S (1.89M shares), VANGUARD GROUP INC (1.72M shares), PERCEPTIVE ADVISORS LLC (1.63M shares), RENAISSANCE TECHNOLOGIES LLC (1.42M shares), Nantahala Capital Management, LLC (1.37M shares), STATE STREET CORP (1.29M shares), FMR LLC (1.04M shares), and FIRST MANHATTAN CO (913K shares).
This table shows the top 115 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.